Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice

Neurobiology of Disease

Volumn 74, Issue , 2015, Pages 204-218

  Stagni, Fiorenza ^a   Giacomini, Andrea ^a   Guidi, Sandra ^a   Ciani, Elisabetta ^a   Ragazzi, Elena ^a   Filonzi, Mirco ^b   De Iasio, Rosaria ^b   Rimondini, Roberto ^a   Bartesaghi, Renata ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

5 HT1A receptor; Alzheimer's disease; Cognitive impairment; Down syndrome; Pharmacotherapy

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APP CARBOSSITERMINAL FRAGMENT BETA; FLUOXETINE; METHYL CPG BINDING PROTEIN 2; SEROTONIN; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG; MECP2 PROTEIN, RAT; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT;

ADULT; ADULTHOOD; AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; COGNITION; CONTROLLED STUDY; DENDRITIC CELL; DOWN SYNDROME; DRUG EFFECT; ENDOSOME; FEMALE; GENETIC TRANSCRIPTION; HIPPOCAMPUS; MALE; MEMORY; MOUSE; NEWBORN; NEWBORN PERIOD; NONHUMAN; ALZHEIMER DISEASE; ANIMAL; C3H MOUSE; C57BL MOUSE; DENDRITE; DISEASE MODEL; DRUG EFFECTS; METABOLISM; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; ANIMALS, NEWBORN; COGNITION; DENDRITES; DISEASE MODELS, ANIMAL; DOWN SYNDROME; ENDOSOMES; FEMALE; FLUOXETINE; HIPPOCAMPUS; MALE; METHYL-CPG-BINDING PROTEIN 2; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURAL STEM CELLS; NEUROGENESIS; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; RECEPTOR, SEROTONIN, 5-HT1A;

EID: 84916920183     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.12.005     Document Type: Article

References (84)

1. Altafaj X., Martin E.D., Ortiz-Abalia J., Valderrama A., Lao-Peregrin C., Dierssen M., Fillat C. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome. Neurobiol. Dis. 2013, 52:117-127.
2. Altman J., Bayer S.A. Migration and distribution of two populations of hippocampal granule cell precursors during the perinatal and postnatal periods. J. Comp. Neurol. 1990, 301:365-381.
3. Amaral D.G., Witter M.P. Hippocampal formation. The Rat Nervous System, G Paxinos 1995, 443-492. Academic Press.
4. Amir R.E., Van den Veyver I.B., Wan M., Tran C.Q., Francke U., Zoghbi H.Y. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 1999, 23:185-188.
5. Anthony J.P., Sexton T.J., Neumaier J.F. Antidepressant-induced regulation of 5-HT(1b) mRNA in rat dorsal raphe nucleus reverses rapidly after drug discontinuation. J. Neurosci. Res. 2000, 61:82-87.
6. Babri S., Badie H.G., Khamenei S., Seyedlar M.O. Intrahippocampal insulin improves memory in a passive-avoidance task in male Wistar rats. Brain Cogn. 2007, 64:86-91.
7. Banasr M., Hery M., Printemps R., Daszuta A. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology 2004, 29:450-460.
8. Bar-Peled O., Gross-Isseroff R., Ben-Hur H., Hoskins I., Groner Y., Biegon A. Fetal human brain exhibits a prenatal peak in the density of serotonin 5-HT1A receptors. Neurosci. Lett. 1991, 127:173-176.
9. Bartesaghi R., Guidi S., Ciani E. Is it possible to improve neurodevelopmental abnormalities in Down syndrome?. Rev. Neurosci. 2011, 22:419-455.
10. Bevins R.A., Besheer J. Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory'. Nat. Protoc. 2006, 1:1306-1311.
11. Bianchi P., Ciani E., Guidi S., Trazzi S., Felice D., Grossi G., Fernandez M., Giuliani A., Calza L., Bartesaghi R. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J. Neurosci. 2010, 30:8769-8779.
12. Boullin D.J., O'Brien R.A. Abnormalities of 5-hydroxytryptamine uptake and binding by blood platelets from children with Down's syndrome. J. Physiol. 1971, 212:287-297.
13. Caccia S., Cappi M., Fracasso C., Garattini S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology (Berl) 1990, 100:509-514.
14. Cai H., Wang Y., McCarthy D., Wen H., Borchelt D.R., Price D.L., Wong P.C. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 2001, 4:233-234.
15. Cassel S., Carouge D., Gensburger C., Anglard P., Burgun C., Dietrich J.B., Aunis D., Zwiller J. Fluoxetine and cocaine induce the epigenetic factors MeCP2 and MBD1 in adult rat brain. Mol. Pharmacol. 2006, 70:487-492.
16. Cataldo A.M., Petanceska S., Peterhoff C.M., Terio N.B., Epstein C.J., Villar A., Carlson E.J., Staufenbiel M., Nixon R.A. App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J. Neurosci. 2003, 23:6788-6792.
17. Cataldo A.M., Mathews P.M., Boiteau A.B., Hassinger L.C., Peterhoff C.M., Jiang Y., Mullaney K., Neve R.L., Gruenberg J., Nixon R.A. Down syndrome fibroblast model of Alzheimer-related endosome pathology: accelerated endocytosis promotes late endocytic defects. Am. J. Pathol. 2008, 173:370-384.
18. Chahrour M., Jung S.Y., Shaw C., Zhou X., Wong S.T., Qin J., Zoghbi H.Y. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 2008, 320:1224-1229.
19. Choi J.H., Berger J.D., Mazzella M.J., Morales-Corraliza J., Cataldo A.M., Nixon R.A., Ginsberg S.D., Levy E., Mathews P.M. Age-dependent dysregulation of brain amyloid precursor protein in the Ts65Dn Down syndrome mouse model. J. Neurochem. 2009, 110:1818-1827.
20. Cirrito J.R., Disabato B.M., Restivo J.L., Verges D.K., Goebel W.D., Sathyan A., Hayreh D., D'Angelo G., Benzinger T., Yoon H., Kim J., Morris J.C., Mintun M.A., Sheline Y.I. Serotonin signaling is associated with lower amyloid-beta levels and plaques in transgenic mice and humans. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:14968-14973.
21. Contestabile A., Fila T., Ceccarelli C., Bonasoni P., Bonapace L., Santini D., Bartesaghi R., Ciani E. Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 2007, 17:665-678.
22. Contestabile A., Fila T., Bartesaghi R., Ciani E. Cell cycle elongation impairs proliferation of cerebellar granule cell precursors in the Ts65Dn mouse, an animal model for Down syndrome. Brain Pathol. 2009, 19:224-237.
23. Contestabile A., Greco B., Ghezzi D., Tucci V., Benfenati F., Gasparini L. Lithium rescues synaptic plasticity and memory in Down syndrome mice. J. Clin. Invest. 2013, 123:348-361.
24. Cossec J.C., Lavaur J., Berman D.E., Rivals I., Hoischen A., Stora S., Ripoll C., Mircher C., Grattau Y., Olivomarin J.C., de Chaumont F., Lecourtois M., Antonarakis S.E., Veltman J.A., Delabar J.M., Duyckaerts C., Di Paolo G., Potier M.C. Trisomy for synaptojanin1 in Down syndrome is functionally linked to the enlargement of early endosomes. Hum. Mol. Genet. 2012, 21:3156-3172.
25. Costa A.C., Scott-McKean J.J. Prospects for improving brain function in individuals with down syndrome. CNS Drugs 2013, 27:679-702.
26. Cowen D.S. Serotonin and neuronal growth factors - a convergence of signaling pathways. J. Neurochem. 2007, 101:1161-1171.
27. Crawley J. What's Wrong With my Mouse? 2007, Wiley-Interscience - A John Wiley & Sons, Inc., Publication.
28. DeLong G.R., Ritch C.R., Burch S. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev. Med. Child Neurol. 2002, 44:652-659.
29. DeVane C.L. Pharmacokinetics of the newer antidepressants: clinical relevance. Am. J. Med. 1994, 97:13S-23S.
30. Dierssen M. Down syndrome: the brain in trisomic mode. Nat. Rev. Neurosci. 2012, 13:844-858.
31. Einarson A., Choi J., Einarson T.R., Koren G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can. J. Psychiatry 2009, 54:242-246.
32. Encinas J.M., Vaahtokari A., Enikolopov G. Fluoxetine targets early progenitor cells in the adult brain. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:8233-8238.
33. Engidawork E., Gulesserian T., Seidl R., Cairns N., Lubec G. Expression of apoptosis related proteins: RAIDD, ZIP kinase, Bim/BOD, p21, Bax, Bcl-2 and NF-kappaB in brains of patients with Down syndrome. J. Neural Transm. Suppl. 2001, 181-192.
34. Fernandez F., Morishita W., Zuniga E., Nguyen J., Blank M., Malenka R.C., Garner C.C. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 2007, 10:411-413.
35. Gallagher M., Burwell R., Burchinal M. Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze. Behav. Neurosci. 1993, 107:618-626.
36. Ginsberg S.D., Mufson E.J., Alldred M.J., Counts S.E., Wuu J., Nixon R.A., Che S. Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. J. Chem. Neuroanat. 2011, 42:102-110.
37. Guidi S., Bonasoni P., Ceccarelli C., Santini D., Gualtieri F., Ciani E., Bartesaghi R. Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome. Brain Pathol. 2008, 18:180-197.
38. Guidi S., Ciani E., Bonasoni P., Santini D., Bartesaghi R. Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with Down syndrome. Brain Pathol. 2011, 21:361-373.
39. Guidi S., Stagni F., Bianchi P., Ciani E., Ragazzi E., Trazzi S., Grossi G., Mangano C., Calza L., Bartesaghi R. Early pharmacotherapy with fluoxetine rescues dendritic pathology in the Ts65Dn mouse model of Down syndrome. Brain Pathol. 2013, 23:129-143.
40. Guidi S., Stagni F., Bianchi P., Ciani E., Giacomini A., De Franceschi M., Moldrich R., Kurniawan N., Mardon K., Giuliani A., Calza L., Bartesaghi R. Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model. Brain 2014, 137:380-401.
41. Hayes R.M., Wu P., Shelton R.C., Cooper W.O., Dupont W.D., Mitchel E., Hartert T.V. Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies. Am. J. Obstet. Gynecol. 2012, 207(49):e41-e49.
42. Hollander E., Phillips A., Chaplin W., Zagursky K., Novotny S., Wasserman S., Iyengar R. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005, 30:582-589.
43. Huang G.J., Ben-David E., Tort Piella A., Edwards A., Flint J., Shifman S. Neurogenomic evidence for a shared mechanism of the antidepressant effects of exercise and chronic fluoxetine in mice. PLoS ONE 2012, 7:e35901.
44. Hunter C.L., Bimonte H.A., Granholm A.C. Behavioral comparison of 4 and 6month-old Ts65Dn mice: age-related impairments in working and reference memory. Behav. Brain Res. 2003, 138:121-131.
45. Hunter C.L., Isacson O., Nelson M., Bimonte-Nelson H., Seo H., Lin L., Ford K., Kindy M.S., Granholm A.C. Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down's syndrome. Neurosci. Res. 2003, 45:437-445.
46. Jiang Y., Mullaney K.A., Peterhoff C.M., Che S., Schmidt S.D., Boyer-Boiteau A., Ginsberg S.D., Cataldo A.M., Mathews P.M., Nixon R.A. Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl. Acad. Sci. U. S. A. 2009, 107:1630-1635.
47. Kuhn D.E., Nuovo G.J., Terry A.V., Martin M.M., Malana G.E., Sansom S.E., Pleister A.P., Beck W.D., Head E., Feldman D.S., Elton T.S. Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains. J. Biol. Chem. 2010, 285:1529-1543.
48. Le Poul E., Boni C., Hanoun N., Laporte A.M., Laaris N., Chauveau J., Hamon M., Lanfumey L. Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuropharmacology 2000, 39:110-122.
49. Liu C., Belichenko P.V., Zhang L., Fu D., Kleschevnikov A.M., Baldini A., Antonarakis S.E., Mobley W.C., Yu Y.E. Mouse models for Down syndrome-associated developmental cognitive disabilities. Dev. Neurosci. 2011, 33:404-413.
50. Lockrow J., Boger H., Bimonte-Nelson H., Granholm A.C. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav. Brain Res. 2010, 221:610-622.
51. Loizzo S., Rimondini R., Travaglione S., Fabbri A., Guidotti M., Ferri A., Campana G., Fiorentini C. CNF1 increases brain energy level, counteracts neuroinflammatory markers and rescues cognitive deficits in a murine model of Alzheimer's disease. PLoS ONE 2013, 8:e65898.
52. Lott I.T., Chase T.N., Murphy D.L. Down's syndrome: transport, storage, and metabolism of serotonin in blood platelets. Pediatr. Res. 1972, 6:730-735.
53. Lott I.T., Murphy D.L., Chase T.N. Down's syndrome. Central monoamine turnover in patients with diminished platelet serotonin. Neurology 1972, 22:967-972.
54. Ly P.T., Wu Y., Zou H., Wang R., Zhou W., Kinoshita A., Zhang M., Yang Y., Cai F., Woodgett J., Song W. Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J. Clin. Invest. 2013, 123:224-235.
55. Lyle R., Gehrig C., Neergaard-Henrichsen C., Deutsch S., Antonarakis S.E. Gene expression from the aneuploid chromosome in a trisomy mouse model of down syndrome. Genome Res. 2004, 14:1268-1274.
56. Mogha A., Guariglia S.R., Debata P.R., Wen G.Y., Banerjee P. Serotonin 1A receptor-mediated signaling through ERK and PKCalpha is essential for normal synaptogenesis in neonatal mouse hippocampus. Transl. Psychiatry 2012, 2:e66.
57. Nelson R.L., Guo Z., Halagappa V.M., Pearson M., Gray A.J., Matsuoka Y., Brown M., Martin B., Iyun T., Maudsley S., Clark R.F., Mattson M.P. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp. Neurol. 2007, 205:166-176.
58. Netzer W.J., Powell C., Nong Y., Blundell J., Wong L., Duff K., Flajolet M., Greengard P. Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model. PLoS ONE 2010, 5:e10943.
59. Nowakowski R.S., Lewin S.B., Miller M.W. Bromodeoxyuridine immunohistochemical determination of the lengths of the cell cycle and the DNA-synthetic phase for an anatomically defined population. J. Neurocytol. 1989, 18:311-318.
60. Olivier J., Akerud H., Kaihola L., Pawluski J., Skalkidou S., Hogberg U., Sundstrom-Poromaa I. The Effects of Maternal Depression and Maternal Selective Serotonin Reuptake Inhibitor Exposure on Offspring 2013, 7. 10.3389/fncel.2013.00073.
61. Park J., Oh Y., Yoo L., Jung M.S., Song W.J., Lee S.H., Seo H., Chung K.C. Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells. J. Biol. Chem. 2010, 285:31895-31906.
62. Pechnick R.N., Zonis S., Wawrowsky K., Cosgayon R., Farrokhi C., Lacayo L., Chesnokova V. Antidepressants stimulate hippocampal neurogenesis by inhibiting p21 expression in the subgranular zone of the hipppocampus. PLoS ONE 2011, 6:e27290.
63. Pedersen L.H., Henriksen T.B., Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19months of age. Pediatrics 2010, 125:e600-e608.
64. Reeves R.H., Irving N.G., Moran T.H., Wohn A., Kitt C., Sisodia S.S., Schmidt C., Bronson R.T., Davisson M.T. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet. 1995, 11:177-184.
65. Reinholdt L.G., Ding Y., Gilbert G.J., Czechanski A., Solzak J.P., Roper R.J., Johnson M.T., Donahue L.R., Lutz C., Davisson M.T. Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn. Mamm. Genome 2011, 22:685-691.
66. Rhin L.L., Claiborne B.J. Dendritic growth and regression in rat dentate granule cells during late postnatal development. Dev. Brain Res. 1990, 54:115-124.
67. Riekkinen P., Riekkinen M., Sirvio J. Cholinergic drugs regulate passive avoidance performance via the amygdala. J. Pharmacol. Exp. Ther. 1993, 267:1484-1492.
68. Roper R.J., St John H.K., Philip J., Lawler A., Reeves R.H. Perinatal loss of TS65DN Down syndrome mice. Genetics 2006, 172:437-443.
69. Sairanen M., Lucas G., Ernfors P., Castren M., Castren E. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J. Neurosci. 2005, 25:1089-1094.
70. Salehi A., Faizi M., Colas D., Valletta J., Laguna J., Takimoto-Kimura R., Kleschevnikov A., Wagner S.L., Aisen P., Shamloo M., Mobley W.C. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci. Transl. Med. 2009, 1:7ra17.
71. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., Belzung C., Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
72. Schlessinger A.R., Cowan W.M., Gottlieb D.I. An autoradiographic study of the time of origin and the pattern of granule cell migration in the dentate gyrus of the rat. J. Comp. Neurol. 1975, 159:149-175.
73. Seo H., Isacson O. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Exp. Neurol. 2005, 193:469-480.
74. Stagni F., Magistretti J., Guidi S., Ciani E., Mangano C., Calza L., Bartesaghi R. Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to Field CA3 in the Ts65Dn mouse model of Down syndrome. PLoS ONE 2013, 8:e61689.
75. Sultan M., Piccini I., Balzereit D., Herwig R., Saran N.G., Lehrach H., Reeves R.H., Yaspo M.L. Gene expression variation in Down's syndrome mice allows prioritization of candidate genes. Genome Biol. 2007, 8:R91.
76. Sun X., Tong Y., Qing H., Chen C.H., Song W. Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome. FASEB J. 2006, 20:1361-1368.
77. Thomas G.M., Huganir R.L. MAPK cascade signalling and synaptic plasticity. Nat. Rev. Neurosci. 2004, 5:173-183.
78. Trazzi S., Mitrugno V.M., Valli E., Fuchs C., Rizzi S., Guidi S., Perini G., Bartesaghi R., Ciani E. APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. Hum. Mol. Genet. 2011, 20:1560-1573.
79. Trazzi S., Fuchs C., De Franceschi M., Mitrugno V., Bartesaghi R., Ciani E. APP-dependent alteration of GSK3ß activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiol. Dis. 2014, (Epub ahead of print). 10.1016/j.nbd.2014.03.003.
80. Whitaker-Azmitia P.M. Serotonin and brain development: role in human developmental diseases. Brain Res. Bull. 2001, 56:479-485.
81. Whittle N., Sartori S.B., Dierssen M., Lubec G., Singewald N. Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development. Pediatrics 2007, 120:e1465-e1471.
82. Yan W., Wilson C.C., Haring J.H. 5-HT1a receptors mediate the neurotrophic effect of serotonin on developing dentate granule cells. Brain Res. Dev. Brain Res. 1997, 98:185-190.
83. Yan W., Wilson C.C., Haring J.H. Effects of neonatal serotonin depletion on the development of rat dentate granule cells. Brain Res. Dev. Brain Res. 1997, 98:177-184.
84. Zhao C., Teng E.M., Summers R.G., Ming G.L., Gage F.H. Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus. J. Neurosci. 2006, 26:3-11.